Get started
Author

M. E. Blair Holbein

Observed names: Blair Holbein, M E Blair Holbein, M. E. B. Holbein, M. E. BLAIR HOLBEIN, M.E. Blair Holbein, ME Blair Holbein
ORCID: 0000-0003-1368-4571
Observed ORCID: 0000-0003-1368-4571
OpenAlex ID: A5103187761
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
2022 · Gyongyi Szabo, Mack Mitchell, et al. · Hepatology · 111
PDF
Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators
2009 · M. E. Blair Holbein · Journal of Investigative Medicine · 103
Intraventricular Hemorrhage and Vitamin E in the Very Low-Birth-Weight Infant: Evidence for Efficacy of Early Intramuscular Vitamin E Administration
1984 · Michael E. Speer, Cindy Blifeld, et al. · PEDIATRICS · 95
Retrolental Fibroplasia and Vitamin E in the Preterm Infant—Comparison of Oral Versus Intramuscular:Oral Administration
1984 · Helen M. Hittner, Michael E. Speer, et al. · PEDIATRICS · 62
Count me in: using a patient portal to minimize implicit bias in clinical research recruitment
2019 · Vaishnavi Kannan, Kathleen E Wilkinson, et al. · Journal of the American Medical Informatics Association · 42
Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?
2015 · M. E. Blair Holbein, Jelena P. Berglund, et al. · Clinical and Translational Science · 38
Exercise-associated collapse in cyclists is unrelated to endotoxemia
1995 · GEOFFREY E. MOORE, M. E. BLAIR HOLBEIN, et al. · Medicine & Science in Sports & Exercise · 29
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
2015 · David E Gerber, Guiyang Hao, et al. · Europe PMC (PubMed Central) · 24
Experience, Perceptions, and Recommendations Concerning COVID-19–Related Clinical Research Adjustments
2021 · David E. Gerber, Thomas Y. Sheffield, et al. · Journal of the National Comprehensive Cancer Network · 23
PDF
Understanding Food and Drug Administration Regulatory Requirements for an Investigational Device Exemption for Sponsor-Investigators
2012 · M. E. Blair Holbein, Jelena Petrovic Berglund · Journal of Investigative Medicine · 17
Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic
2021 · Misty Gravelin, Jeanne Wright, et al. · Journal of Clinical and Translational Science · 11
PDF
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
2018 · M. E. Blair Holbein, Kevin J. Weatherwax, et al. · Journal of Clinical and Translational Science · 11
PDF
Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award Consortium: Developing and Implementing a Sponsor-Investigators Training Program
2014 · M. E. Blair Holbein, Jelena Petrovic Berglund, et al. · Journal of Investigative Medicine · 8
Warning Letters to Sponsor-Investigators at Academic Health Centres – The Regulatory “Canaries in a Coal Mine”
2013 · Erin K O’Reilly, ME Blair Holbein, et al. · Clinical and investigative medicine · 4
PDF
Correspondence
1991 · M.E. Blair Holbein, James Griener, et al. · American Journal of Kidney Diseases · 3
Institutionally Chartered Data and Safety Monitoring Boards: Structured Approaches to Assuring Participant Safety in Clinical Research
2021 · Blair Holbein, Marie T Rape, et al. · Journal of Investigative Medicine · 2
Via media: Role and responsibilities of the independent safety officer
2019 · M. E. B. Holbein, Barbara N. Hammack, et al. · Journal of Clinical and Translational Science · 1
PDF
Cephalosporin confusion—one simple solution?
1991 · M. E. Blair Holbein, Vicki S. Crane · American Journal of Health-System Pharmacy · 1
Intraventricular Hemorrhage (ivh) & Vitamin E (ve) in Very Low Birth Weight Infants: Efficacy of Early Im Administration
1984 · Michael E Speer, Cindy Blifeld, et al. · Pediatric Research · 1
Understanding food and drug administration (FDA) regulatory requirements for investigational new drug applications (IND) for sponsor-investigators
2012 · M. E. Blair Holbein
Works count: 20
Citation count: 580
H-index: 11
I10-index: 12
Year
Topic
Type